Advertisement

 

 

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015.

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015.
Author Information (click to view)

Choe PG, Perera RAPM, Park WB, Song KH, Bang JH, Kim ES, Kim HB, Ko LWR, Park SW, Kim NJ, Lau EHY, Poon LLM, Peiris M, Oh MD,


Choe PG, Perera RAPM, Park WB, Song KH, Bang JH, Kim ES, Kim HB, Ko LWR, Park SW, Kim NJ, Lau EHY, Poon LLM, Peiris M, Oh MD, (click to view)

Choe PG, Perera RAPM, Park WB, Song KH, Bang JH, Kim ES, Kim HB, Ko LWR, Park SW, Kim NJ, Lau EHY, Poon LLM, Peiris M, Oh MD,

Advertisement

Emerging infectious diseases 2017 07 1523(7) 1079-1084 doi 10.3201/eid2307.170310

Abstract

We investigated the kinetics of the Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing and spike protein antibody titers over the course of 1 year in 11 patients who were confirmed by reverse transcription PCR to have been infected during the outbreak in South Korea in 2015. Robust antibody responses were detected in all survivors who had severe disease; responses remained detectable, albeit with some waning, for <1 year. The duration of viral RNA detection (but not viral load) in sputum significantly correlated with the antibody response magnitude. The MERS S1 ELISA antibody titers correlated well with the neutralizing antibody response. Antibody titers in 4 of 6 patients who had mild illness were undetectable even though most had evidence of pneumonia. This finding implies that MERS-CoV seroepidemiologic studies markedly underestimate the extent of mild and asymptomatic infection. Obtaining convalescent-phase plasma with high antibody titers to treat MERS will be challenging.

Submit a Comment

Your email address will not be published. Required fields are marked *

11 − 6 =

[ HIDE/SHOW ]